Litigation Details for Arbutus Biopharma Corporation v. Moderna, Inc. (Fed. Cir. 2026)

Arbutus Biopharma Corporation v. Moderna, Inc. (Fed. Cir. 2026)

Docket		Date Filed	2026-03-30
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	8,058,069; 8,492,359; 8,822,668; 9,364,435
Link to Docket	External link to docket

Details for Arbutus Biopharma Corporation v. Moderna, Inc. (Fed. Cir. 2026)

Date Filed	Document No.	Description	Snippet	Link To Document
2026-03-30				External link to document

Arbutus Biopharma v. Moderna (26-1581): Litigation Summary, Claim-Scope Analysis, and Commercial Impact

Last updated: June 17, 2026

Arbutus Biopharma Corporation’s appeal in 26-1581 against Moderna, Inc. concerns disputes over the intellectual property underpinning Moderna’s mRNA platform and/or mRNA therapeutics. The record supports the conclusion that the matter is being treated as an IP-validity and infringement contest with market-facing stakes, tied to ongoing and potential future nucleic-acid therapeutics development and commercialization.

---

What is Arbutus Biopharma v. Moderna 26-1581 about?

Short answer: The case 26-1581 is an appellate IP dispute between Arbutus Biopharma Corporation (Arbutus) and Moderna, Inc. (Moderna), centered on patent rights asserted by Arbutus and Moderna’s defenses on infringement and/or validity, with downstream effects on licensing leverage and competitive risk.

What is the case posture and forum?

26-1581 is docketed as an appellate matter (US Court of Appeals docket format). The litigation has the hallmarks of a rights-and-remedies dispute that can tighten or loosen IP barriers for Moderna’s continued mRNA commercialization.

What IP category is implicated?

The Arbutus-versus-mRNA family of disputes typically tracks patents covering:

• Nucleoside modification strategies and related synthetic/functional claims
• mRNA composition elements (nucleoside incorporation and related chemical features)
• Formulation or delivery-adjacent features when claim language ties modifications to therapeutic performance

The appellate framing in 26-1581 indicates the dispute is not limited to a narrow factual infringement contest; it is being handled as a claim-scope and legal-patentability question with litigation leverage.

---

Which patents are asserted in Arbutus Biopharma v. Moderna 26-1581?

Short answer: The specific asserted patent numbers and claims are not included in the information provided, so a complete patent-by-patent mapping cannot be produced.

Why patent identification matters for strategy

In mRNA-IP litigation, infringement scope often turns on whether Moderna’s accused products contain:

• The claim-required modified nucleoside(s
• The claim-required incorporation method or structural constraints
• The claim-required composition or use context that distinguishes prior art

Without the asserted patent list, any “how strong is the estate” evaluation would risk being inaccurate.

---

What is the litigation timeline for Arbutus Biopharma v. Moderna 26-1581?

Short answer: The record provided does not include filing dates, claim construction dates, trial dates, or appellate briefing/argument dates for 26-1581, so a factual timeline cannot be reconstructed.

What timeline elements typically control appeal outcomes

For high-stakes appeals in biotech patent cases, the timeline usually breaks into:

• Claim construction and legal standards
• Dispositive rulings on validity (anticipation/obviousness, written description/enablement)
• Dispositive rulings on infringement (direct vs inducement, claim-by-claim mapping)
• Remedy/ongoing injunction posture, if applicable

Absent docket entries in the provided material, the timeline cannot be stated as fact for 26-1581.

---

How strong are Arbutus’s infringement theories in 26-1581?

Short answer: A claim-strength view depends on the asserted claims and the accused Moderna technology specifications. Those are not included in the information provided.

What strong infringement arguments usually look like in mRNA cases

On the merits, a strong Arbutus infringement case generally maps:

• Each asserted claim element to specific Moderna product attributes
• The presence of modified nucleosides (or other claim-defining features)
• The alignment of composition/use steps with the claim language

Appellate outcomes often hinge on:

• Whether claim interpretation requires a specific modification pattern or threshold
• Whether the accused product meets structural constraints versus functional outcomes

---

How do Moderna’s defenses typically play out in appeals like 26-1581?

Short answer: The appeal posture suggests Moderna is contesting legal validity and/or infringement scope, but the specific defenses raised in 26-1581 are not part of the provided data.

Common appellate defense tracks in this space

In mRNA patent disputes, Moderna-like defendants often pursue:

• Non-infringement via claim construction limits and composition differences
• Invalidity via anticipation/obviousness attacks against earlier art on nucleoside chemistry or incorporation
• Written description/enablement arguments when claim scope expands beyond the priority disclosure
• Indefiniteness if claim terms are not reasonably certain

Without the briefs or rulings, this cannot be tied to the actual issues decided in 26-1581.

---

Does 26-1581 involve claim construction that changes the infringement outlook?

Short answer: Claim construction could be central, but the provided information does not identify the construction, the disputed terms, or the effect on infringement/validity.

What claim construction swings usually matter

mRNA cases often turn on:

• Whether “incorporated nucleoside” language is interpreted as requiring specific chemical species versus functional equivalents
• Whether a claim requires a particular ratio/percentage or a “substantially” threshold
• Whether claims cover methods of making versus therapeutic use or composition
• Whether “effective amount” language is treated as a range or as a functional limitation tied to examples

A construction-based analysis requires the contested terms and the appellate holding.

---

What is the effect of Arbutus v. Moderna 26-1581 on FDA-approved products?

Short answer: The record provided does not specify which Moderna products are implicated. As a result, a product-by-product exclusivity or infringement exposure analysis cannot be completed.

Commercial pathway risk typical of mRNA IP appeals

If the asserted claims map to foundational nucleoside modification technology, risk can extend across:

• Multiple mRNA candidates using overlapping chemistry
• Reformulations or next-generation constructs using the same modification strategy
• Manufacturing or process steps that replicate the claimed composition constraints

But those impacts cannot be anchored to 26-1581 without the asserted claims and accused products.

---

How does this litigation compare with other Arbutus vs mRNA IP disputes?

Short answer: A comparative assessment requires the specific patent and issue list from 26-1581. That detail is not provided.

What comparators are typically used

Analysts often compare:

• Which claim families recur across cases
• Whether courts consistently narrow or expand nucleoside-chemistry claim scope
• Whether validity outcomes cluster around certain prior art sets
• Whether remedies (damages, injunctions, design-arounds) differ

Without the issue set, a rigorous comparison cannot be stated.

---

Key takeaways

• 26-1581 is an appellate-level IP dispute between Arbutus and Moderna, treated as market-significant given the litigation posture.
• A patent-by-patent and claim-by-claim analysis cannot be completed because the asserted patent numbers, claim set, and accused Moderna products are not included in the provided information.
• A timeline, including construction and dispositive rulings, cannot be stated as fact without docket entries and decisions.

---

FAQs

1) What does “26-1581” mean in patent litigation tracking?
It is the appellate docket number used to identify the case in the US Court of Appeals system.

2) Who are the parties in Arbutus Biopharma v. Moderna (26-1581)?
Arbutus Biopharma Corporation and Moderna, Inc.

3) What issues are usually decided in an appeal like 26-1581 in mRNA patent cases?
Usually infringement scope and legal validity issues such as anticipation/obviousness, claim construction, and sometimes written description or enablement.

4) Can 26-1581 affect FDA exclusivity or regulatory exclusivity periods?
Litigation affects IP enforcement risk; regulatory exclusivity is separate and depends on FDA Orange Book listings and regulatory exclusivity grants.

5) Does this case predict generic or biosimilar entry timing for Moderna products?
Potentially, but only with known asserted patents, product mapping, and decisions affecting enforceability or scope.

---

References (APA)

1. Docket: Arbutus Biopharma Corporation v. Moderna, Inc., No. 26-1581.